Selective PARP Inhibitor Improves Survival in Breast Cancer Trial
American Association for Cancer Research
Saruparib has higher selectivity for PARP1, improving safety and tolerability compared to existing first-gen PARP inhibitors
The application is the first of its kind to be recognized by the FDA